Comparative Pharmacology
Head-to-head clinical analysis: MOBIC versus PONSTEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOBIC versus PONSTEL.
MOBIC vs PONSTEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
7.5-15 mg orally once daily. Maximum 15 mg/day.
250 mg orally every 6 hours as needed, not to exceed 1 g per day, for no longer than 7 days.
None Documented
None Documented
Terminal elimination half-life: ~20 hours (range 13–20 h); allows once-daily dosing; prolonged in elderly (25–26 h) and hepatic impairment.
2-4 hours (terminal elimination half-life); clinical context: duration of analgesia 4-6 hours; accumulates with renal impairment
Renal: ~50% as unchanged drug and metabolites; biliary/fecal: ~50% via feces; enterohepatic recirculation occurs.
Primarily renal (70-80% as glucuronide conjugates and unchanged drug); biliary/fecal (20-30%)
Category C
Category C
Nonsteroidal Anti-Inflammatory Drug
Nonsteroidal Anti-Inflammatory Drug